Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

Summary

The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).

Timeline

Start

2015-08-31

Primary completion

2020-12-08

Completion

2020-12-08

Outcome

Outcome not reported

Stopped: “Study termination by the Sponsor”

Drugs

Indications